Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00828074 · ClinicalTrials.gov registry record · Phase 1
Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00828074 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 46 participants.
The verdict
NCT00828074, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with vinorelbine may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of sorafenib when given together with vinorelbine and to see how well they work in treating women with stage IV breast cancer.
Interventions
- DRUG sorafenib tosylate
- DRUG vinorelbine ditartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2008-11 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00828074
The ClinicalTrials.gov registry entry for NCT00828074 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sorafenib tosylate is the first listed.
NCT00828074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00828074 about?
NCT00828074 is a clinical study titled "Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer". RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib t...
What is the current status of trial NCT00828074?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2008-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00828074?
The interventions under investigation include: sorafenib tosylate (DRUG), vinorelbine ditartrate (DRUG).
Who is sponsoring clinical trial NCT00828074?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.